Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- 1 June 2010
- journal article
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 66 (2) , 532-540
Abstract
Summary An outcome‐adaptive Bayesian design is proposed for choosing the optimal dose pair of a chemotherapeutic agent and a biological agent used in combination in a phase I/II clinical trial. Patient outcome is characterized as a vector of two ordinal variables accounting for toxicity and treatment efficacy. A generalization of the Aranda‐Ordaz model (1981, Biometrika 68, 357–363) is used for the marginal outcome probabilities as functions of a dose pair, and a Gaussian copula is assumed to obtain joint distributions. Numerical utilities of all elementary patient outcomes, allowing the possibility that efficacy is inevaluable due to severe toxicity, are obtained using an elicitation method aimed to establish consensus among the physicians planning the trial. For each successive patient cohort, a dose pair is chosen to maximize the posterior mean utility. The method is illustrated by a trial in bladder cancer, including simulation studies of the method's sensitivity to prior parameters, the numerical utilities, correlation between the outcomes, sample size, cohort size, and starting dose pair.Keywords
This publication has 25 references indexed in Scilit:
- Recent Developments in Adaptive Designs for Phase I/II Dose-Finding StudiesJournal of Biopharmaceutical Statistics, 2007
- Simultaneously optimizing dose and schedule of a new cytotoxic agentClinical Trials, 2007
- An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinationsStatistics in Medicine, 2006
- Adaptive Dose Selection Using Efficacy-Toxicity Trade-Offs: Illustrations and Practical ConsiderationsJournal of Biopharmaceutical Statistics, 2006
- Bivariate isotonic design for dose‐finding with ordered groupsStatistics in Medicine, 2005
- A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose‐Finding TrialBiometrics, 2005
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma TrialJournal of the American Statistical Association, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- A Method for the Detailed Assessment of the Appropriateness of Medical TechnologiesInternational Journal of Technology Assessment in Health Care, 1986
- On two families of transformations to additivity for binary response dataBiometrika, 1981